Paper

Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis

European Journal of Preventive Cardiology · 2026 · Stephen J Nicholls, Imre Pavo, Deepak L Bhatt et al.